CADTH Therapeutic Review of Multiple Myeloma Unique in Many Aspects
The CADTH Therapeutic Review of treatments for transplant-ineligible multiple myeloma patients represents several firsts for the organization. It is CADTH’s first therapeutic review in oncology, and its first involving international collaboration.
CADTH is working with the Erasmus School of Health Policy and Management (ESHPM) in the Netherlands on both the clinical and economic research and will use real-world data from a Canadian database and the outcomes of the network meta-analyses to develop a living economic model on the cost-effectiveness of treatment sequences.
It means that new therapies can be incorporated into the model in a timely manner, as they become available in Canada. Further, this living economic model will assist payers as they look to manage their formularies and identify the most cost-effective treatment sequences.
In addition to international collaboration, Canada’s national multiple myeloma patient advocacy group is also contributing to the project. Myeloma Canada surveyed patients to complement patient group input that was submitted to CADTH as part of previous reimbursement reviews of multiple myeloma treatments.